<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet12802</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-12802</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Обоснование подходов к коррекции нарушений липидного обмена и неалкогольной жировой болезни печени у детей с экзогенно-конституциональным ожирением</article-title><trans-title-group xml:lang="en"><trans-title>Substantiation of approaches to the correction of lipid metabolism disorders and non-alcoholic fatty liver disease in children with exogenous obesity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1820-299X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поварова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Povarova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Поварова Оксана Викторовна, кандидат медицинских наук</p><p>119991, г. Москва, Ломоносовский проспект, д. 27, корп. 1</p><p>Researcher ID: R-3090-2016;</p><p>Scopus Author ID: 6603347164;</p><p>eLibrary SPIN: 6244-2772</p></bio><bio xml:lang="en"><p>Oxana V. Povarova, MD, PhD]; адрес: 119991, Россия, г. Москва, Ломоносовский проспект, д. 27, корп. 1 [address: 27/1, Lomonosov avenue, 119991, Moscow</p><p>Researcher ID: R-3090-2016;</p><p>Scopus Author ID: 6603347164;</p><p>eLibrary SPIN: 6244-2772</p></bio><email xlink:type="simple">oxpovarova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7106-3338</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Городецкая</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorodetskaya</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Городецкая Евгения Ароновна, кандидат биологических наук, доцент</p><p>Москва</p><p>Scopus Author ID: 6603700637;</p><p>eLibrary ID: 82831</p></bio><bio xml:lang="en"><p>Evgeniya A. Gorodetskaya, Ph in biology</p><p>Moscow</p><p>Scopus Author ID: 6603700637;</p><p>eLibrary ID: 82831</p></bio><email xlink:type="simple">gorodeag@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0385-3474</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куляк</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulyak</surname><given-names>O. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куляк Олеся Юрьевна, кандидат фармацевтических наук</p><p>Москва</p><p>Researcher ID: AAO-6219-2021;</p><p>Scopus Author ID:</p><p>57039988900; eLibrary SPIN: 9697-1220</p></bio><bio xml:lang="en"><p>Olesya J. Kulyak, Ph in pharmacy</p><p>Moscow</p><p>Researcher ID: AAO-6219-2021;</p><p>Scopus Author ID: 57039988900;</p><p>eLibrary SPIN: 9697-1220</p></bio><email xlink:type="simple">kulyak-olesya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8787-6819</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демяненко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Demyanenko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Демяненко Александра Николаевна, кандидат медицинских наук</p><p>Смоленск</p><p>eLibrary SPIN: 6889-8349</p></bio><bio xml:lang="en"><p>Alexandra N. Demyanenko, MD, PhD</p><p>Smolensk</p><p>eLibrary SPIN: 6889-8349</p></bio><email xlink:type="simple">alex-glam@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3230-1337</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алимова</surname><given-names>И. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Alimova</surname><given-names>I. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алимова Ирина Леонидовна, доктор медицинских наук, профессор</p><p>Смоленск</p><p>eLibrary SPIN: 4583-9822</p></bio><bio xml:lang="en"><p>Irina L. Alimova, MD, PhD, Professor</p><p>Smolensk</p><p>eLibrary SPIN: 4583-9822</p></bio><email xlink:type="simple">iri-alimova@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0068-2788</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каленикова</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalenikova</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Каленикова Елена Игоревна, доктор фармацевтических наук, профессор</p><p>Москва</p><p>Scopus Author ID: 6603796631;</p><p>eLibrary SPIN: 5868-6998</p></bio><bio xml:lang="en"><p>Elena I. Kalenikova, Ph in pharmacy, Professor</p><p>Moscow</p><p>Scopus Author ID: 6603796631;</p><p>eLibrary SPIN: 5868-6998</p></bio><email xlink:type="simple">eikaleni@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8942-4851</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Медведев</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Medvedev</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Медведев Олег Стефанович, доктор медицинских наук, профессор</p><p>Москва</p><p>Researcher ID: A-5674-2016;</p><p>Scopus Author ID: 7103337682;</p><p>eLibrary SPIN: 7696-3683</p></bio><bio xml:lang="en"><p>Oleg S. Medvedev, MD, PhD, Professor</p><p>Moscow</p><p>Researcher ID: A-5674-2016;</p><p>Scopus Author ID: 7103337682;</p><p>eLibrary SPIN: 7696-3683</p></bio><email xlink:type="simple">oleg.medvedev@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московский государственный университет имени М.В. Ломоносова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Смоленский государственный медицинский университет</institution><country>Russian Federation</country></aff><aff xml:lang="en"><institution>Smolensk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>08</day><month>03</month><year>2022</year></pub-date><volume>19</volume><issue>1</issue><fpage>19</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Поварова О.В., Городецкая Е.А., Куляк О.Ю., Демяненко А.Н., Алимова И.Л., Каленикова Е.И., Медведев О.С., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Поварова О.В., Городецкая Е.А., Куляк О.Ю., Демяненко А.Н., Алимова И.Л., Каленикова Е.И., Медведев О.С.</copyright-holder><copyright-holder xml:lang="en">Povarova O.V., Gorodetskaya E.A., Kulyak O.Y., Demyanenko A.N., Alimova I.L., Kalenikova E.I., Medvedev O.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/12802">https://www.omet-endojournals.ru/jour/article/view/12802</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Учитывая участие окислительного стресса в патогенезе ожирения, представляет интерес исследование плазменного уровня коэнзима Q10 в корреляционной взаимосвязи с изменениями биохимических показателей, характеризующих нарушения липидного обмена и функционального состояния печени.</p></sec><sec><title>Цель</title><p>Цель. Исследовать содержание коэнзима Q10 и его взаимосвязь с показателями липидограммы и печеночных ферментов у детей с экзогенно-конституциональным ожирением.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В одноцентровое одномоментное исследование были включены дети (средний возраст 12 лет) 2 групп: основной (n=40; SD индекса массы тела (ИМТ) &gt;+2,0) и контрольной (n=32; -1,0≤SD ИМТ≤+1,0). У всех детей оценивали SD ИМТ, УЗИ печени, липидограмму, ферменты печени (аланинаминотрансферазу (АЛТ), аспартатаминотрансферазу (АСТ)), плазменный уровень коэнзима Q10.</p></sec><sec><title>Результаты</title><p>Результаты. Уровни коэнзима Q10 в сравниваемых группах были сопоставимы (p&gt;0,05) и не отличались у пациентов с различной степенью ожирения. У пациентов основной группы уровень липопротеидов высокой плотности был ниже, а уровень липопротеидов низкой плотности — выше показателей группы контроля. Самые высокие показатели липопротеидов высокой плотности были у пациентов с 1-й степенью ожирения, а триглицеридов — у пациентов с 4-й степенью ожирения. Повышенный уровень холестерина чаще отмечался у детей основной группы (8 (20%); р=0,037). 15 (37,5%) пациентов основной группы имели дислипидемию (р&lt;0,001). В контрольной группе установлена прямая взаимосвязь уровня коэнзима Q10 и общего холестерина (r=0,474; р=0,009), в основной группе подобная взаимосвязь отмечалась только у пациентов с 1-й степенью ожирения (r=0,548; р=0,035). Показатели АСТ в обследуемых группах не различались, однако уровни АЛТ и соотношения АЛТ/АСТ были выше у пациентов основной группы (p&lt;0,001). При этом самые высокие показатели АЛТ и соотношения АЛТ/АСТ отмечались у пациентов с 4-й степенью ожирения. У 18 (45%) детей основной группы отношение АЛТ/АСТ было ≥1 (p&lt;0,001), при этом у 14 (80%) из них по данным УЗИ печени отмечалось увеличение обеих долей и изменение ее структуры. В контрольной группе установлена прямая взаимосвязь уровня коэнзима Q10 и отношения АЛТ/АСТ (r=0,412; р=0,023), в основной группе — индекса атерогенности и АЛТ/АСТ (r=0,436; р=0,006), а у пациентов с 1-й степенью ожирения также коэнзима Q10 и АЛТ (r=0,875; р&lt;0,001).</p></sec><sec><title>Заключение</title><p>Заключение. Нарушение адекватного обеспечения холестерина коэнзимом Q10 у детей с экзогенно-конституциональным ожирением отражает патогенетическую роль окислительного стресса в развитии дислипидемий и неалкогольной жировой болезни печени и может служить показанием для назначения препаратов коэнзима Q10 с целью коррекции данных осложнений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: According to the involvement of oxidative stress in the pathogenesis of obesity, the plasma level of coenzyme q10 in the correlation relationship with lipid metabolism disorders and functional liver state is of interest to study.</p></sec><sec><title>AIM</title><p>AIM: Substantiation of approaches to the correction of lipid metabolism disorders and non-alcoholic fatty liver disease in children with exogenous obesity based on the content of coenzyme Q10 and its relationship with lipid profile and liver enzymes.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: The single-center cross-sectional study enlisted the control (n=32, -1.0≤BMI SD score ≤+2.0) and obese (n=40, BMI SD score&gt;+2.0) groups of children with the mean age of 12 yr. In all children BMI, lipidogram, liver enzymes (ALT and AST), plasma coenzyme Q10 and liver ultrasound examination were assessed.</p></sec><sec><title>RESULTS</title><p>RESULTS: Patients of both groups were comparable (p&gt; 0.05) in age and gender. The level of coenzyme Q10 in the compared groups was comparable (p&gt; 0.05) and did not differ in patients with different degrees of obesity. According to the results of the study of the lipid profile in the obese children, the level of HDL was lower, and the level of LDL was higher than that in control group. The highest value of HDL was obtained in the patients with the 1st degree of obesity and the highest level of triglycerides — in the patients with the 4th degree of obesity. The control group demonstrated moderate correlations between endogenous coenzyme Q10 and total cholesterol (r=0.474, p=0.009) which persists in patients with the first degree of obesity (r = 0.548, p = 0.035). There was no difference in AST in the study groups, however, the main group demonstrated elevated ALT and ALT/AST ratio (p &lt;0.001). The highest ALT and ALT / AST ratio were observed in patients with greatest degree of obesity. Eighteen obese children (45%) had ALT / AST ratio ≥1 (in the control group –one patient (3%) (p &lt;0.001), while fourteen patients showed liver enlargement and structure change according to ultrasound (80%). The control group demonstrated moderate correlations between endogenous coenzyme Q10 and total cholesterol (r=0.474, p=0.009) and between coenzyme Q10 and ALT / AST ratio (r=0.412, p=0.023) . In the obese group there was correlation between AI and ALT / AST (r = 0.436, p = 0.006) and in patients with the 1st degree of obesity — between also coenzyme Q10 and ALT (r = 0.875, p &lt;0.001).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: The disturbances in adequate control of cholesterol by coenzyme Q10 in obese children possibly confirming the involvement of oxidative stress in the pathogenesis of dyslipidemia and non-alcoholic fatty liver disease can serve as indication to use coenzyme Q10 in order to correct these complications.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>дети</kwd><kwd>коэнзим Q10</kwd><kwd>дислипидемия</kwd><kwd>неалкогольная жировая болезнь печени</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>coenzyme Q10</kwd><kwd>dyslipidemia</kwd><kwd>non-alcoholic fatty liver disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wang LX, Gurka MJ, DeBoer MD. Metabolic syndrome severity and lifestyle factors among adolescents. Minerva Pediatr. 2018;70:467-475. doi: https://doi.org/10.23736/S0026-4946.18.05290-8</mixed-citation><mixed-citation xml:lang="en">Wang LX, Gurka MJ, DeBoer MD. Metabolic syndrome severity and lifestyle factors among adolescents. Minerva Pediatr. 2018;70:467-475. doi: https://doi.org/10.23736/S0026-4946.18.05290-8</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Garwood P, Chaib F, Brogan C. Tenfold increase in childhood and adolescent obesity in four decades: new study by Imperial College London and WHO.[cited 2017 October 11]. Available from: https://www.who.int/news/item/11-10-2017-tenfold-increase-in-childhoodand-adolescent-obesity-in-four-decades-new-study-by-imperialcollege-london-and-who</mixed-citation><mixed-citation xml:lang="en">Garwood P, Chaib F, Brogan C. Tenfold increase in childhood and adolescent obesity in four decades: new study by Imperial College London and WHO.[cited 2017 October 11]. Available from: https:// www.who.int/news/item/11-10-2017-tenfold-increase-in-childhoodand-adolescent-obesity-in-four-decades-new-study-by-imperialcollege-london-and-who</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">WHO: obesity and overweight. [cited 2020 April 4]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-andoverweight</mixed-citation><mixed-citation xml:lang="en">WHO: obesity and overweight. [cited 2020 April 4]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-andoverweight</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Бокова Т.А. Неалкогольная жировая болезнь печени и основные компоненты метаболического синдрома у детей // Экспериментальная и клиническая гастроэнтерология. — 2020. — Т. 173. — №1. — С. 15-20. doi: https://doi.org/10.31146/1682-8658-ecg-173-1-15-20</mixed-citation><mixed-citation xml:lang="en">Bokova TA. Non-alcoholic fatty liver disease in children: relationship with the main components of metabolic syndrome in children. Experimental and Clinical Gastroenterology. 2020;173 (1):15-20. (In Russ.) doi: https://doi.org/10.31146/1682-8658-ecg-173-1-15-20</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Weihe P, Weihrauch-Blüher S. Metabolic syndrome in children and adolescents: diagnostic criteria, therapeutic options and perspectives. Curr Obes Rep. 2019;8:472-479. doi: https://doi.org/10.1007/s13679-019-00357-x.</mixed-citation><mixed-citation xml:lang="en">Weihe P, Weihrauch-Blüher S. Metabolic syndrome in children and adolescents: diagnostic criteria, therapeutic options and perspectives. Curr Obes Rep. 2019;8:472-479. doi: https://doi.org/10.1007/s13679-019-00357-x.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">DeBoer MD. Assessing and managing the metabolic syndrome in children and adolescents. Nutrients. 2019;11:1788-1790. doi: https://doi.org/10.3390/nu11081788</mixed-citation><mixed-citation xml:lang="en">DeBoer MD. Assessing and managing the metabolic syndrome in children and adolescents. Nutrients. 2019;11:1788-1790. doi: https://doi.org/10.3390/nu11081788</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndr Relat Disord. 2015;10:423-444. doi: https://doi.org/10.1089/met.2015.0095</mixed-citation><mixed-citation xml:lang="en">Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndr Relat Disord. 2015;10:423-444. doi: https://doi.org/10.1089/met.2015.0095</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации «Ожирение у детей» 2021 г. Доступно по: http://cr.minzdrav.gov.ru/recomend/229_2. Ссылка активна на 12.10.2021.</mixed-citation><mixed-citation xml:lang="en">Klinicheskiere komendacii «Ozhirenie u detej» 2021. (In Russ.). Доступно по: http://cr.minzdrav.gov.ru/recomend/229_2. Link active on 12.10.2021.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kalenikova EI, Gorodetskaya EA, Medvedev OS. Pharmacokinetics of coenzyme Q10. Bull Exp Biol Med. 2008;146 (3):313-316. doi: https://doi.org/10.1007/s10517-008-0270-8</mixed-citation><mixed-citation xml:lang="en">Kalenikova EI, Gorodetskaya EA, Medvedev OS. Pharmacokinetics of coenzyme Q10. Bull Exp Biol Med. 2008;146 (3):313-316. doi: https://doi.org/10.1007/s10517-008-0270-8</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Коденцова В.М., Вржесинская О.А., Кошелева О.В., и др. Оценка обеспеченности витаминами-антиоксидантами пациентов с ожирением с позиций риска развития сопутствующих заболеваний // Ожирение и метаболизм. — 2020. — Т. 17. — №1. — С. 22-32. doi: https://doi.org/10.14341/omet10144</mixed-citation><mixed-citation xml:lang="en">Kodentsova VM, Vrzhesinskaya OA, Kosheleva OV, et al. Antioxidant vitamin status of obese patients in terms of the risk of comorbidities. Obesity and metabolism. 2020;17 (1):22-32. (In Russ.). doi: https://doi.org/10.14341/omet10144</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Поварова О.В., Городецкая Е.А., Каленикова Е.И., Медведев О.С. Метаболические маркеры и окислительный стресс в патогенезе ожирения у детей // Рос. вестн. перинатол. и педиатр. — 2020. — Т. 65. — №1. — С. 22-29. doi: https://doi.org/10.21508/1027-4065-2020-65-1-22-29</mixed-citation><mixed-citation xml:lang="en">Povarova OV, Gorodetskaya EA, Kalenikova EI, Medvedev OS. Metabolic markers and oxidative stress in children’s obesity pathogenesis. Russian Bull Perinatol Pediatr. 2020;65 (1):22-29. (In Russ.). doi: https://doi.org/10.21508/1027-4065-2020-65-1-22-29</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Vona R, Gambardella L, Cittadini C, et al. Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. Oxid Med Cell Longev. 2019;2019:1-19. doi: https://doi.org/10.1155/2019/8267234</mixed-citation><mixed-citation xml:lang="en">Vona R, Gambardella L, Cittadini C, et al. Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. Oxid Med Cell Longev. 2019;2019:1-19. doi: https://doi.org/10.1155/2019/8267234</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Casagrande D, Waib PH, Jordão Júnior AA. Mechanisms of action and effects of the administration of Coenzyme Q10 on metabolic syndrome. J Nutr Intermed Metab. 2018;13:26-32. doi: https://doi.org/10.1016/j.jnim.2018.08.002</mixed-citation><mixed-citation xml:lang="en">Casagrande D, Waib PH, Jordão Júnior AA. Mechanisms of action and effects of the administration of Coenzyme Q10 on metabolic syndrome. J Nutr Intermed Metab. 2018;13:26-32. doi: https://doi.org/10.1016/j.jnim.2018.08.002</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gvozdjakova A, Kucharska J, Tkacov M, et al. Ratio of lipid parameters to coenzyme Q10 could be used as biomarker of the development of early complications of obesity in children. Bratisl. Lek. Listy. 2012;113:21-25. doi: https://doi.org/10.4149/BLL_2012_005</mixed-citation><mixed-citation xml:lang="en">Gvozdjakova A, Kucharska J, Tkacov M, et al. Ratio of lipid parameters to coenzyme Q10 could be used as biomarker of the development of early complications of obesity in children. Bratisl. Lek. Listy. 2012;113:21-25. doi: https://doi.org/10.4149/BLL_2012_005</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Muhtagorlu S, Koca SO, Cetin I, et al. Investigation of ischemia modified albumin and coenzyme Q10 levels in obese children with metabolic syndrome. TJB. 2016;41:443-449. doi: https://doi.org/10.1515/tjb-2016-0147</mixed-citation><mixed-citation xml:lang="en">Muhtagorlu S, Koca SO, Cetin I, et al. Investigation of ischemia modified albumin and coenzyme Q10 levels in obese children with metabolic syndrome. TJB. 2016;41:443-449. doi: https://doi.org/10.1515/tjb-2016-0147</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Menke T, Niklowitz P, de Sousa G, et al. Comparison of coenzyme Q10 plasma levels in obese and normal weight children. Clin. Chim. Acta. 2004;349:121-127. doi: https://doi.org/10.1016/j.cccn.2004.06.015</mixed-citation><mixed-citation xml:lang="en">Menke T, Niklowitz P, de Sousa G, et al. Comparison of coenzyme Q10 plasma levels in obese and normal weight children. Clin. Chim. Acta. 2004;349:121-127. doi: https://doi.org/10.1016/j.cccn.2004.06.015</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Павловская Е.В., Строкова Т.В., Пырьева Е.А., Шилина Н.М. Неалкогольная жировая болезнь печени у детей с ожирением: современные аспекты диагностики и лечения // Вопросы детской диетологии. — 2021. — Т. 19. — №2. — С. 53–61. doi: https://doi.org/10.20953/1727-5784-2021-2-53-61</mixed-citation><mixed-citation xml:lang="en">Pavlovskaya EV, Strokova TV, Pyriva EA, Shilina NM. Non-alcoholic fatty liver disease in obese children: modern aspects of diagnosis and treatment. Pediatric Nutrition. 2021;19 (2):53-61. (In Russ.). doi: https://doi.org/10.20953/1727-5784-2021-2-53-61</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kawamoto R, Kohara K, Kusunoki T, et al. Alanine aminotransferase/ aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Cardiovasc Diabetol. 2012;11:1-8. doi: https://doi.org/10.1186/1475-2840-11-117</mixed-citation><mixed-citation xml:lang="en">Kawamoto R, Kohara K, Kusunoki T, et al. Alanine aminotransferase/ aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Cardiovasc Diabetol. 2012;11:1-8. doi: https://doi.org/10.1186/1475-2840-11-117</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Homsanit M, Sanguankeo A, Upala S, Udol K. Abnormal liver enzymes in Thai patients with metabolic syndromes. J Med Assoc Thai. 2012;95:444.</mixed-citation><mixed-citation xml:lang="en">Homsanit M, Sanguankeo A, Upala S, Udol K. Abnormal liver enzymes in Thai patients with metabolic syndromes. J Med Assoc Thai. 2012;95:444.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ajith TA. Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 2018;45:413-421. doi: https://doi.org/10.1111/1440-1681.12886</mixed-citation><mixed-citation xml:lang="en">Ajith TA. Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 2018;45:413-421. doi: https://doi.org/10.1111/1440-1681.12886</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Botham KM, Napolitano M, Bravo E. The emerging role of disturbed CoQ metabolism in nonalcoholic fatty liver disease development and progression. Nutrients. 2015;7:9834-9846. doi: https://doi.org/10.3390/nu7125501</mixed-citation><mixed-citation xml:lang="en">Botham KM, Napolitano M, Bravo E. The emerging role of disturbed CoQ metabolism in nonalcoholic fatty liver disease development and progression. Nutrients. 2015;7:9834-9846. doi: https://doi.org/10.3390/nu7125501</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
